发明授权
- 专利标题: SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES
- 专利标题(中): 螺旋体蛋白吡咯并嘧啶
-
申请号: EP04715273.1申请日: 2004-02-27
-
公开(公告)号: EP1601677B1公开(公告)日: 2006-06-28
- 发明人: IRIE, Osamu , IWASAKI, Genji , MASUYA, Keiichi , MIYAKE, Takahiro , TENO, Naoki
- 申请人: Novartis AG , Novartis Pharma GmbH
- 申请人地址: Lichtstrasse 35 4056 Basel CH
- 专利权人: Novartis AG,Novartis Pharma GmbH
- 当前专利权人: Novartis AG,Novartis Pharma GmbH
- 当前专利权人地址: Lichtstrasse 35 4056 Basel CH
- 代理机构: de Weerd, Petrus G.W.
- 优先权: GB0304640 20030228
- 国际公布: WO2004076455 20040910
- 主分类号: C07D487/04
- IPC分类号: C07D487/04 ; A61P29/00 ; A61K31/00
摘要:
The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.
公开/授权文献
- EP1601677A1 SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES 公开/授权日:2005-12-07
信息查询